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Background: About 10 to 20% of children in West European countries have atopic dermatitis (AD), often as part of
the atopic syndrome. The full atopic syndrome also consists of allergic asthma, allergic rhinitis and food allergy.
Treatment approaches for atopic dermatitis and asthma include intermittent anti-inflammatory therapy with
corticosteroids, health education and self-management training. However, symptoms persist in a subgroup of
patients. Several observational studies have shown significant improvement in clinical symptoms in children and
adults with atopic dermatitis or asthma after treatment at high altitude, but evidence on the efficacy when
compared to treatment at sea level is still lacking.
Methods/Design: This study is a pragmatic randomized controlled trial for children with moderate to severe AD
within the atopic syndrome. Patients are eligible for enrolment in the study if they are: diagnosed with moderate to
severe AD within the atopic syndrome, aged between 8 and 18 years, fluent in the Dutch language, have internet
access at home, able to use the digital patient system Digital Eczema Center Utrecht (DECU), willing and able to
stay in Davos for a six week treatment period. All data are collected at the Wilhelmina Children’s Hospital and
DECU. Patients are randomized over two groups. The first group receives multidisciplinary inpatient treatment
during six weeks at the Dutch Asthma Center in Davos, Switzerland. The second group receives multidisciplinary
treatment during six weeks at the outpatient clinic of the Wilhelmina Children’s Hospital, Utrecht, the Netherlands.
The trial is not conducted as a blind trial. The trial is designed with three components: psychosocial, clinical and
translational. Primary outcomes are coping with itch, quality of life and disease activity. Secondary outcomes
include asthma control, medication use, parental quality of life, social and emotional wellbeing of the child and
translational parameters.
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Discussion: The results of this trial will provide evidence for the efficacy of high altitude treatment compared to
treatment at sea level for children with moderate to severe AD.
Trial Registration: Current Controlled Trials ISRCTN88136485.
Keywords: Atopic dermatitis, Atopic eczema, Asthma, Atopic syndrome, Children, Coping, Quality of life, High
altitude treatment, Multidisciplinary treatment, RCTBackground
About 10 to 20% of children in West European countries
are diagnosed with atopic dermatitis (AD) [1]. AD and
allergic asthma (AA) are the most common chronic dis-
eases in children. They can be considered different man-
ifestations of the atopic syndrome which also includes
allergic rhinitis and food allergy [2]. It has been esti-
mated that 30 to 36% of the children diagnosed with AD
aged years or younger will be diagnosed with asthma at
age 6 years or older [3]. The reverse has also been dem-
onstrated; in a cohort of children diagnosed with asthma
aged between six and nine years, 20% had developed AD
after nine years of follow-up [4]. The majority of chil-
dren with AD are currently treated on an outpatient
basis. Treatment approaches include topical treatment
with emollients, anti-inflammatory therapy with topical
immunosuppressive-like agents (corticosteroids and cal-
cineurin inhibitors), anti-microbial treatment and educa-
tional programs, according to current guidelines [5,6].
However, symptoms persist in a subgroup of children
with moderate to severe AD. Often these children have an
extensive treatment history and are unable to gain suffi-
cient control of their disease. It has been shown that a
multidisciplinary approach to AD treatment is beneficial
for children who do not respond well to regular treatment,
and often results in sustained clinical improvement [7,8].
The multidisciplinary model includes medical and psycho-
social evaluation and treatment, and educates the children
and their parents using a stepwise approach to the man-
agement of AD [8]. Psychosocial evaluation is important
because children have to learn to cope with the specific
problems associated with living with a chronic disease [9].
Furthermore, they have to learn to adhere to strict medi-
cinal regimes, which are time consuming. Often they are
restricted in activities, such as sports, swimming or out-
side play. Social and emotional problems may occur be-
cause of the distinguished appearance and characteristics
of AD [10]. Sleep deprivation due to nightly symptoms of
itch may lead to tiredness, mood changes and impaired
psychosocial functioning of the child and his/her family
[10]. AD has a significant negative impact on the quality
of life of children and their parents. With increasing AD
severity, reported quality of life decreases further [11,12].
Since the 1950s Dutch children with asthma are re-
ferred to the Dutch Asthma Center in Davos, located at1560 m altitude in the Swiss Alps, for ‘high altitude’
treatment [13]. Important characteristics of the alpine
climate are the dry air, the low exposure to allergens
(such as house dust mite and fungi), and the increased ex-
posure to UV radiation [13]. There is also a relative lack
of pollution [14]. Several observational studies have shown
significant improvement in quality of life and clinical
symptoms (Fev1 (forced expiratory volume in 1 second),
FeNO (fraction of exhaled nitric oxide) and SCORAD
(scoring atopic dermatitis) among others) in children
and adults with AD and asthma after treatment at high
altitude [15-21]. However, no randomized trials have
been done to investigate the superiority of high altitude
treatment compared to treatment at sea level in improv-
ing quality of life or disease activity in children with AD
or asthma.
In the DAVOS trial, we compare multidisciplinary treat-
ment at high altitude and sea level in a pragmatic random-
ized design. The objective of this study is to find the most
effective treatment strategy for children with difficult to
treat AD. This paper describes the study design and the
interventions.
Methods/Design
Design and setting
A pragmatic randomized controlled trial was designed in
collaboration with the Department of Pediatric Derma-
tology/Allergology in the Wihelmina Children’s Hospital
(a national referral center in the Netherlands for children
with moderate to severe AD and the atopic syndrome)
and the high altitude clinic Dutch Asthma Center Davos
in Switzerland. Dutch children with moderate to severe
AD are either treated during six weeks at the Dutch
Asthma Center Davos (inpatient treatment) or at the
Wilhelmina Children’s Hospital (outpatient treatment).
All children are expected to be included in the study
within a time period of four years.
The trial consists of three different components: psy-
chosocial, clinical and translational. The children in the
study will be extensively monitored on these three aspects
at study inclusion and during the study period. The study
period includes the actual enrollment in the study, a six
week intervention period and follow-up measurements at
six weeks and six months after the intervention (Figure 1).
Enrollment and all follow-up measurements will be done
Assessed for eligibility 
Excluded
Allocated to intervention in Dutch Astmacenter 
Davos (6 weeks multidisciplinary high altitude 
treatment)
Allocated to intervention in Wilhelmina 
Children’s Hospital (6 weeks multidisciplinary 
outpatient treatment)
Allocation
Follow-Up
Design of multidisciplinary 
treatment plan
Enrollment
Randomization
Assessment
before start of the intervention
T0
Assessment
direct after the intervention
T1
Assessment
6 weeks after the intervention
T2
Assessment
6 months after the intervention
T3
Assessment
at start of participation in trial
T-1
Figure 1 Flowchart of study design.
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Center Utrecht (DECU) will be used for data collection
and communication [22]. Within this digital portal possi-
bilities for e-consulting, self-management training and on-
line monitoring are combined.Ethical considerations
This study follows the Dutch Medical Research Involv-
ing Human Subjects Act 1998 (WMO) and the Helsinki
Declaration principles 2008, meaning that the legal repre-
sentatives of all participants will sign a written informed
consent, stating that participation can be withdrawn at
any time without any negative consequences concerning
their current or future medical treatment. All study proce-
dures have been reviewed and approved by the Medical
Ethics Committee of the Utrecht Medical Center, the
Netherlands (reference 09-192/K).Participants
The DAVOS trial is designed for children in the
Netherlands with difficult to treat AD who are unable to
gain sufficient control of their disease with current treat-
ment strategies. Children are eligible for enrolment in
the study if they are: diagnosed with moderate to severe
AD within the atopic syndrome; aged between 8 and
18 years; fluent in the Dutch language; have internet
access at home; able to use the Digital Eczema Center
Utrecht; and willing and able to stay in Davos for a six
week treatment period.
Children are not eligible for enrolment if they are cur-
rently participating in another study.
Recruitment, inclusion procedure and consent
The DAVOS trial is a national trial conducted in the
Netherlands. Children with moderate to severe AD will be
recruited from the outpatient clinic of the Wilhelmina
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try. Dutch dermatologists, pediatricians, allergists, general
practitioners and patient support groups were informed
about the trial in journals, conferences and using online
media.
Children and/or their parents who are interested in
the trial can register themselves directly in the DECU. A
questionnaire with items regarding allergic complaints,
use of (topical) immunosuppressive therapy such as
corticosteroids, and more specific questions regarding
AD activity (including a self-administered eczema area
and severity index (SA-EASI)), questions on nightly com-
plaints of itch and sleeping behavior and, if relevant, ques-
tions on asthma, rhinitis and food allergy complaints has
to be answered in order to register. Possible study partici-
pants are invited by the dermatologist to the outpatient
clinic and assessed for eligibility. They are not required to
stop or change their medication at this point. Children
who fulfill the inclusion criteria are then informed about
the study. If they are interested in participating in the trial,
they are invited for a complete evaluation by the multidis-
ciplinary team at the Wilhelmina Children’s Hospital, and
informed consent is signed.Sample size
The sample size calculation for the psychosocial part is
based on the primary outcome coping with itch, mea-
sured with the JUCKKI, children’s itching cognitions
questionnaire [23]. A difference of five points is ex-
pected between the groups on the subscale catastrophi-
sation (negative thoughts that have gone out of control).
This difference was based on a study by Staab et al. on
the effect of educational programs in children and ado-
lescents with AD [24]. In this study, the SD of both
groups was 7.6.
An additional sample size calculation was carried out
for the clinical part of the trial. This was based on the
primary outcome disease activity, measured with the
SA-EASI [25]. Based on the study by Staab et al., in
which SCORAD was used to measure disease activity, a
difference of 10 points between the groups and a SD of
15 for each group was expected [24,26].
With a power of 80%, 36 children are needed in each
group. Assuming a drop-out rate of 10%, 40 children will
be assigned to each of the two study conditions.Randomization
Children are randomly assigned to either intervention
or control groups. Randomization is done in SAS (stat-
istical analysis system) with a custom made program by
an external data manager using a covariate-adaptive
randomization method, controlled for age and diagnosis
of asthma [27].Multidisciplinary treatment
The multidisciplinary team consists of a dermatologist,
a pediatric allergist or pediatrician, psychologist and
(dermatology/research) nurse. Weekly multidisciplinary
evaluation during the intervention between the involved
professional teams in Utrecht and Davos takes place
using video conference. In this way, expertise is being
combined and optimal care for all included patients is
guaranteed. A short summary of discussed topics is pro-
vided in the patient record in the DECU.
Before randomization and start of the intervention a
multidisciplinary treatment plan is developed, with in-
put from both multidisciplinary teams, to make sure
the treatment goals can be achieved under either inter-
vention and control conditions. Based on the intake
(history of received treatment, psychological question-
naires and intelligence outcomes), specific problem
areas are identified and each healthcare professional
writes down the treatment goals and strategy in a treat-
ment plan. Psychosocial as well as clinical treatment
goals are formulated. Examples of treatment goals are:
adherence to treatment; influence and acceptance of
AD in everyday life, including distinguished appearance;
correct application of topical corticosteroids; coping
with itch; sleep disturbances; and knowing what to
do during an exacerbation. Planned interventions to
achieve the goals are specified, as well as the respon-
sible healthcare professional. There are no treatment
restrictions during the trial. The treatment plan is dis-
cussed with the child and their parents and may be
modified if needed. External professionals who are
already involved with the child, for example the refer-
ring physician, nurses or social workers, are invited to
participate during the study through the DECU, with
permission of the child and their parents. In this way,
optimal continuation of transmural treatment for the
patient is made possible after the end of the study in
the home region of the patient.
The intervention in Davos
Children are admitted to the Dutch Asthma Center Davos
for a period of six weeks in groups of four children. The
children attend a school integrated into the clinic. There
are also social workers who accommodate the group, and
each child has his/her own mentor.
The treatment program consists of several fixed ele-
ments. Every day, a group physical activity is organized
under supervision of a physiotherapist, such as fitness,
swimming or outdoor activities. Weekly individual
treatment sessions take place with the pediatrician, the
psychologist alternating with the psychomotor therapist,
and the physiotherapist (if needed). The nurse monitors
correct application of topical treatment in individual
sessions with each child twice daily. In these individual
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weekly theme. The content of the individual consulta-
tions depends on the problems described in the treat-
ment plan. Children and their parents are separated
during the six week treatment period, however parents
usually visit once.
Control condition in Utrecht
Recently, a new multidisciplinary intervention has been
developed for children with AD combining education,
involvement of both dermatologists, pediatricians, psy-
chologists and nurses, and the use of the DECU. Chil-
dren are seen during half a day at the outpatient clinic
on a weekly basis for a period of six weeks. During this
period they have three consultations with the dermatolo-
gist, five consultations with the dermatological nurse,
three consultations with the pediatric allergist and three
consultations with the psychologist. The content of the
individual consultations depends on the treatment goals
described in the treatment plan.
In the third week a group medical appointment (also
known as group consultation) is scheduled for the chil-
dren and their parents separately, about coping with AD
and compliance [28]. It is a substitute for an individual
appointment with a clinician during which children and
their parents discuss their personal experiences and ad-
vise and support each other.
A description of intervention and control conditions is
provided in Table 1.
Follow-up period
There is a six month follow-up period during which all
children are assessed three times at the Wilhelmina
Children’s Hospital: immediately after the intervention,
six weeks after the intervention and six months after the
intervention, which is the end of the follow-up period.
During the entire follow-up period, children are encour-
aged to use the self-management tools in the DECU. In
case of questions and/or exacerbations, they can contactTable 1 Overview of control and intervention conditions
Treatment location
Wilhelmina Children's Hospital
Multidisciplinary team Dermatologist, pediatric allergist, psychologist,
dermatology nurse
Treatment program Three individual consultations with dermatolog
pediatrician and psychologist
One group consultation (children and parents
separate)
Educational program Five individual consultations with the
dermatology nurse
Treatment setting Outpatient
Environment Own home in the Netherlandsthe dermatology nurse with an e-consultation and, if
needed, an appointment with the dermatologist is made.
All children are encouraged to play sports, for example
at FitKids, a Dutch organization that facilitates physical
activity programs for children with a chronic disease
under supervision of a children’s physiotherapist [29].Primary and secondary outcomes
The primary outcomes of this study are coping with itch
and quality of life of the child for the psychosocial part
and disease activity for the clinical part. Coping levels
are measured with the JUCKKI questionnaire for chil-
dren (aged 8 to 12 years) and the JUCKJU questionnaire
for adolescents (aged 13 to 18 years) [23]. Quality of life
is assessed with the CDQLI questionnaire [30]. Disease
activity is assessed with the SA-EASI [25].
Secondary outcomes for the psychosocial part include
social and emotional wellbeing of the child, feelings of
autonomy and fear, quality of life and stress levels of the
parents.
Secondary outcomes for the clinical part include medica-
tion use, TARC (thymus and activation-regulated chemo-
kine), total and specific IgE (Immunoglobulin E), asthma
control parameters such as FeNO (fraction of exhaled ni-
tric oxide), ACQ (asthma control questionnaire), PAQLQ
(pediatric asthma quality of life questionnaire), BHR (bron-
chial hyperresponsiveness) and spirometric variables such
as FEV1 (forced expiratory volume in 1 second), FVC
(forced vital capacity) and their ratio (FEV1/FVC). During
the follow-up period, the number of flares, the number
of dermatologist/pediatric/psychologist appointments,
e-consultations and emergency visits or hospital admis-
sions are recorded.
At each time point in the study, questionnaires are
filled in by the child and his/her parents, blood samples
are taken from the child, and lung function is assessed.
A detailed overview of all parameters and measurements
is provided in Table 2.Dutch Asthma Center Davos
Pediatrician, psychologist, nurse, psychomotor therapist,
physiotherapist, social workers
ist, Six individual consultations with pediatrician, four with the
psychologist, three with the psychomotor therapist
Physical activity program under supervision of physiotherapist
Twice daily individual consultations with the dermatology
nurse
Inpatient
Clinic in Swiss alpine environment
Table 2 Study assessments
Assessment Measured with T-1 T0 T1 T2 T3
Coping with itch and disease JUCKKI-COPECI (8-12 yr) or JUCKJU-COPEJU (13-18 yr) [23] x x x x x
Disease-specific quality of life CDQLI [31] x x x x x
Disease activity and control (AD) EASI [33] x x x x x
SA-EASI [25] x x x x x
Used topical corticosteroids x x x x x
TARC [34] x x x x x
Disease activity and control (Asthma) ACQ [35] x x x x x
PAQLQ [36] x x
Lung function test x x x x x
FeNO x x x x x
Used medication x x x x x
Metacholine provocation x x x x x
Serum Total IgE x x
Specific IgE: inhalation/food: ImmunoCAP x x
Specific IgE: inhalation/food: ImmunoCAP ISAC x
Eosinophils x x x x
Cytokine profile x x x x
Questionnaires Social demographic information x
Intelligence test [37] x
SF-36 [38,39] x
CBCL [40,41] x
Corticosteroid use x x x
NPV-J [42] x
TRF [40] x
CBSK/CBSA [43,44] x x x
ZBV-K [45] x x x x
PUL (>12 yr) [46] x x x
Quality of life (parents) [47] x x x x
ZBV [48] x x x
NOSI-K [49] x x x
NOSI-events [49] x x
Other Maximal cycle ergometer test x x
Bacterial colonization of the skin x x x x
Bacterial colonization of the nose x x x x
Skin strips for protease activity x x x x
ACQ, asthma control questionnaire; CBCL, child behavior checklist; CBSK, self-perception profile for children; CBSA, self-perception profile for adolescents; CDQLI,
the children’s dermatology life quality index; COPEKI/COPEJU, coping with disease questionnaire; EASI, eczema area and severity index; FeNO, fraction of exhaled
nitric oxide; IgE, Immunoglobulin E; ImmunoCAP, ImmunoCAP system (Thermo Fisher Scientific, Uppsala, Sweden); ImmunoCAP ISAC, Immunosolid-phase allergen
chip (Thermo Fisher Scientific, Uppsala, Sweden); JUCKKI/JUCKJU, itching cognitions questionnaire; NOSI-events, parental stress index-events; NOSI-K, parental
stress index- short form; NPV-J, Dutch personality questionnaire-youth version; PAQLQ, pediatric asthma quality of life questionnaire;
PUL, positive outcome list; SA-EASI, self-administered eczema area and severity index; SF-36, short form health survey; TARC, thymus and activation-regulated
chemokine; T-1, assessment at start of participation in trial; T0, assessment before start of the intervention; T1, assessment direct after the intervention; T2,
assessment six weeks after the intervention; T3, assessment six months after the intervention; TRF, teacher report form; ZBV, state-trait anxiety inventory; ZBV-K,
state-trait anxiety inventory for children.
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In this study two sources of electronic data are used.
The DECU gives a detailed overview of the interventionand follow-up period and contains the data from the ques-
tionnaires, assessments and e-consultations. Additional
patient data is extracted from the electronic patient file in
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all data will be combined into one SPSS (Statistical Prod-
uct and Service Solutions) database.
Data will be analyzed on an intention to treat basis. To
examine whether there is a significant difference on the
primary outcomes between the intervention and control
group, a mixed-effects regression model will be used.
Fixed effects for time, intervention group and the
time*group interaction will be included in the model in
order to examine the differences between the groups over
time. To adjust for possible curvilinearity a squared term
for time will be included in the model. A random inter-
cept and random slope per child will be included in order
to account for repeated measures within children. Baseline
values of the outcome variables are included as fixed co-
variates to examine their possible impact on the observed
treatment effect.
Data relating to asthma outcomes will be analyzed sep-
arately for all children diagnosed with asthma. All analyses
conform to a specified plan. There are no interim analyses
or stopping rules.
Discussion
The DAVOS trial is a pragmatic randomized controlled
trial that investigates the effect of multidisciplinary treat-
ment at high altitude compared to sea level on coping,
quality of life and disease activity in children with mod-
erate to severe AD within the atopic syndrome. It is
designed as a pragmatic trial, which fits best with our
objective to find a new intervention with optimal treat-
ment results for children with difficult to treat AD [31].
In this study we compare inpatient treatment in a high
altitude clinic in Switzerland with outpatient treatment
in a national expert center in the Netherlands. We chose
for outpatient treatment in the Wilhelmina Children’s
Hospital, because it currently offers the most specialized
and intensive treatment in the Netherlands for this
group of patients. It is most efficient to organize the in-
volved medical disciplines to see the patients consecu-
tively in an outpatient setting. Furthermore, we want to
evaluate the best treatment for children with difficult to
treat AD that minimizes the burden but maximizes the
result. This means that if it is possible to reach signifi-
cant clinical improvement with an intense six week out-
patient program in the Netherlands, this is the preferred
choice compared to a six week inpatient treatment in
the Netherlands. Also, it would not be possible to ex-
trapolate results from inpatient treatment in an aca-
demic hospital compared to a peripheral hospital. We
believe that in this trial design, we are comparing the
best options for treatment that are also likely to be car-
ried out in practice after the end of the trial.
There are several differences between the intervention
and control conditions, such as the differences in setting:inpatient and outpatient, own environment and change
to alpine environment. During the intervention in Davos,
adherence to treatment is more likely to increase due to
the clinical setting. Children are separated from their
parents which can be perceived as an extra burden for the
child. It may also be an advantage, especially when the
coping strategy of the child is negatively influenced by the
coping strategies of the family [32].
All children in both interventions are discussed in
weekly videoconferencing sessions with both multidis-
ciplinary teams. AD treatment in both interventions is
supervised by a single dermatologist in the Netherlands
to minimize differences. Corticosteroid use is reduced or
increased according to similar stepwise plans in both
treatment arms. The educational plan is co-developed by
both centers and consists of similar elements in both
treatment arms. It is administered by the nurse and
there is frequent contact between the nurses of both
treatment arms.
The pragmatic nature of our trial will not allow us to
find out how or why the interventions work, or which
elements of the interventions contribute most to the ob-
served treatment effects. Therefore we will study effect-
iveness: the long-term benefit of either treatment in
routine clinical practice [31].
This study has several strengths. Children that partici-
pate come from all over the Netherlands. They often have
an extensive treatment history and still experience an
impaired quality of life, despite treatment according to
current guidelines. In this study, children receive multidis-
ciplinary treatment with individualized treatment goals ei-
ther in their own environment or in an alpine clinical
environment. The results of this trial will show which
would be the most appropriate approach to provide
treatment that results in sufficient long-term disease
control for children with difficult to treat AD. The find-
ings of our trial will be directly applicable in practice in
the Netherlands.
The study also has potential drawbacks. It is an intense
period for the study participants in which they have to
visit the Wilhelmina Children’s Hospital several times
for the scheduled assessments. Each assessment means a
missed day of work for the parents and a missed school
day for the child. This may lead to a larger drop-out rate
than anticipated and it may take a lot of effort to keep
the study participants motivated for all assessments. In
this study neither the study participants nor the health-
care professionals assessing outcomes were blinded to
the received intervention. This may cause bias for the
more subjective outcome measures, such as the SA-
EASI.
To the best of our knowledge, this is the first random-
ized trial that compares high altitude treatment with
treatment at sea level in children with difficult to treat
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on the characteristics of these children. We hope to pro-
vide evidence for an intervention that gives the best re-
sults in terms of coping, quality of life and disease
activity for this group of children.
Trial status
The first patient was included in the study in September
2010. At the moment patient recruitment and data col-
lection is in progress. We expect to complete patient re-
cruitment by May 2014.
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